Drug updated on 12/11/2024
| Dosage Form | Injection (subcutaneous: 125 mg/0.5 mL, 63 mg/0.5 mL, 94 mg/0.5 mL; Intramuscular: 125 mcg/0.5 mL) |
| Drug Class | Interferon beta |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Latest News
Summary
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- Peginterferon beta-1a (Plegridy) showed a significant reduction in relapse rates over 24 months in patients with relapsing-remitting multiple sclerosis (RRMS) compared to placebo (relative risk (RR) 0.63; 95% confidence interval (CI), 0.52 to 0.77) and demonstrated better effectiveness than Teriflunomide (RR 0.78) and IFN beta-1a (Avonex) (RR 0.87). However, it was less effective than Alemtuzumab and Ocrelizumab (both with RR 0.49), and Natalizumab and Fingolimod.
- Peginterferon beta-1a did not significantly increase the rate of serious adverse events (SAEs) compared to placebo, with a risk ratio (RR) of 1.07 (95% CI 0.66 to 1.74), based on very low-certainty evidence.
- The rate of treatment discontinuation due to adverse events was notably higher for Peginterferon beta-1a, with a risk ratio of 3.46 (95% CI 1.44 to 8.33) and an odds ratio of 1.48 (95% CI 0.99 to 2.20), indicating a significant increase in withdrawal compared to placebo.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Plegridy (peginterferon beta-1a) Prescribing Information. | 2023 | Biogen Inc., Cambridge, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. | 2024 | The Cochrane Database of Systematic Reviews |
| Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis | 2023 | The Cochrane Database of Systematic Reviews |
| Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis | 2020 | Journal of Neurology |